Despite the PDUFA date being extended by three months for Merus’ zenocutuzumab, Truist Securities analyst Asthika ...
Merus’ zenocutuzumab is nearing FDA approval, and petosemtamab shows promise. Learn why MRUS stock could rise as the company ...
In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on Merus (MRUS – Research Report), with a price ...
The FDA is set to decide on four promising therapies in the next two weeks, including a CAR T for acute lymphoblastic ...
Mirae Asset Global Investments Co. Ltd. increased its position in shares of Merus (NASDAQ:MRUS – Free Report) by 24.7% in the 3rd quarter, Holdings Channel.com reports. The fund owned 2,467 shares of ...
Andrew Berens, an analyst from Leerink Partners, maintained the Buy rating on Merus (MRUS – Research Report). The associated price target ...
Third Quarter 2024 Results Key Financial Results Revenue: US$11.8m (up 6.7% from 3Q 2023).
Zacks.com on MSN5d
Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue EstimatesMerus N.V. (MRUS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $0.43 per share a year ago. These figures are ...
Phase 3 registrational trials evaluating petosemtamab in combination with pembrolizumab in 1L and petosemtamab monotherapy in 2/3L r/m HNSCC enrolling Petosemtamab in 2L+ r/m HNSCC interim clinical ...
This update in the health sector highlights major developments including DiaSorin's significant profit growth, GSK's RSV ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback